scispace - formally typeset
M

Matthew D. Gallovic

Researcher at University of North Carolina at Chapel Hill

Publications -  24
Citations -  772

Matthew D. Gallovic is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Adjuvant & Dextran. The author has an hindex of 14, co-authored 21 publications receiving 504 citations. Previous affiliations of Matthew D. Gallovic include Ohio State University & Durham University.

Papers
More filters
Journal ArticleDOI

A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination

TL;DR: The encapsulated cGAMP elicited no observable toxicity in animals and achieved protective immunity against a lethal influenza challenge seven months post‐immunization when using CDN adjuvant doses up to 100‐fold lower than previous reports.
Journal ArticleDOI

Synthesis and characterization of acetalated dextran polymer and microparticles with ethanol as a degradation product.

TL;DR: This study aims to enhance the biocompatibility of acetalated dextran-type polymers to allow their use in high volume clinical applications such as multiple dosing and tissue engineering.
Journal ArticleDOI

A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8+ T cell-mediated anti-tumor immunity.

TL;DR: In this article, a biodegradable polymer acetalated dextran (Ace-DEX) was used to formulate PAMP microparticles (MPs) in order to enhance intracellular delivery.
Journal ArticleDOI

Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists

TL;DR: Polymeric Ace-DEX MPs loaded with STING and TLR7/8 agonists represent a potent cellular and humoral vaccine adjuvant, and codelivery of cGAMP MPs and soluble Toll-like receptor 7/ 8 agonist resiquimod elicited the broadest cytokine response.
Journal ArticleDOI

Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses.

TL;DR: A differential response suggests the need for distinct, flexible control over adjuvant or antigen delivery and its impact on immune response modulation.